Celldex Q2 2023 Earnings Report

Reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Takeaways

Celldex Therapeutics reported its Q2 2023 financial results, with total revenue of $0.3 million and a net loss of $30.5 million, or ($0.65) per share. The company's cash, cash equivalents, and marketable securities totaled $252.7 million as of June 30, 2023, expected to fund operations through 2025.

Phase 2 CSU enrollment was completed ahead of schedule, with topline data expected by the end of 2023.

Phase 1b PN data is anticipated in Q4 2023.

The first patient was dosed in the Phase 2 EoE study.

Barzolvolimab was highlighted at EAACI, positioning it as a potential best-in-class treatment.

Previous year: -$0.77

-15.6%